Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematological malignancy arising from plamacytoid dendritic cell precursors [1]. Its neoplastic cells have a distinct immunophenotype with expression of markers like CD4, CD56, BDCA-2, CD123, TCL1 and being negative for myeloperoxidase [2]. In the past, several different nomenclatures have been used to describe this malignancy until 2008 when the World Health Organization (WHO) classification described BPDCN as an entity under the family of acute myeloid leukemia (AML) and related neoplasms [3].
Source: Leukemia Research - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research